XRCC1 Arg399Gln Polymorphism Confers Risk of Breast Cancer in American Population: a Meta-analysis of 10846 Cases and 11723 Controls

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Feb 4

PMID 24489692

Citations 13

Authors

Tao Bu

Li Liu

Yong Sun

Li Zhao

Yang Peng

Shudong Zhou

Lixia Li

Sidong Chen

Yanhui Gao

Affiliations

Soon will be listed here.

Abstract

Background: In the X-ray repair cross-complementing group 1 (XRCC1) gene, a polymorphism, Arg399Gln (rs25487), has been shown to change neoconservative amino acid and thus result in alternation of DNA repair capacity. Numerous studies have investigated the association between Arg399Gln and breast cancer risk in the American population, but yielding inconsistent results. This study aimed to clarify the role of this polymorphism in susceptibility to breast cancer.

Methods: Literatures were searched in multiple databases including PubMed, Springer Link, Ovid, EBSCO and ScienceDirect databases up to April 2013. A comprehensive meta-analysis was conducted to estimate the overall odds ratio (OR), by integrating data from 18 case control studies of 10846 cases and 11723 controls in the American population.

Results: Overall, significant association was observed between the Arg399Gln polymorphism and breast cancer risk under the random-effects model (OR for dominant model = 1.12, 95% CI: 1.02-1.24, P heterogeneity = 0.003; OR for additive model = 1.07, 95% CI: 1.01-1.14, P heterogeneity = 0.017). Further sensitivity analysis supported the robust stability of this current result by showing similar ORs before and after removal of a single study.

Conclusions: This meta-analysis suggests that the XRCC1 Arg399Gln polymorphism may significantly contribute to susceptibility of breast cancer in the American population.

Citing Articles

Racial Disparity in Anthracycline-induced Cardiotoxicity in Breast Cancer Patients.

Balaji S, Antony A, Tonchev H, Scichilone G, Morsy M, Deen H Biomedicines. 2023; 11(8).

PMID: 37626782 PMC: 10452913. DOI: 10.3390/biomedicines11082286.

GA Genotype of the Arg280His Polymorphism on The Gene: Genetic Susceptibility Genotype in Differentiated Thyroid Carcinomas?.

Kirnap N, Tutuncu N, Yalcin Y, Cebi H, Tutuncu T, Nar A Balkan J Med Genet. 2021; 24(1):73-80.

PMID: 34447662 PMC: 8366467. DOI: 10.2478/bjmg-2021-0003.

XRCC1 Gene Polymorphism Increases the Risk of Hepatocellular Carcinoma in Egyptian Population.

Naguib M, Helwa M, Soliman M, Abdel-Samiee M, Eljaky A, Hammam O Asian Pac J Cancer Prev. 2020; 21(4):1031-1037.

PMID: 32334466 PMC: 7445958. DOI: 10.31557/APJCP.2020.21.4.1031.

Polymorphism of DNA repair genes in breast cancer.

Smolarz B, Michalska M, Samulak D, Romanowicz H, Wojcik L Oncotarget. 2019; 10(4):527-535.

PMID: 30728902 PMC: 6355183. DOI: 10.18632/oncotarget.26568.

The association of polymorphic markers Arg399Gln of XRCC1 gene, Arg72Pro of TP53 gene and T309G of MDM2 gene with breast cancer in Kyrgyz females.

Isakova J, Talaibekova E, Aldasheva N, Vinnikov D, Aldashev A BMC Cancer. 2017; 17(1):758.

PMID: 29132330 PMC: 5683588. DOI: 10.1186/s12885-017-3762-y.

References

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

Wu K, Su D, Lin K, Luo J, Au W . XRCC1 Arg399Gln gene polymorphism and breast cancer risk: a meta-analysis based on case-control studies. Asian Pac J Cancer Prev. 2012; 12(9):2237-43. View

Ali M, Meza J, Rogan E, Chakravarti D . Prevalence of BER gene polymorphisms in sporadic breast cancer. Oncol Rep. 2008; 19(4):1033-8. View

Yuan P, Liu L, Wu C, Zhong R, Yu D, Wu J . No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy. Cancer Biol Ther. 2010; 10(9):854-9. DOI: 10.4161/cbt.10.9.13238. View

Smith T, Levine E, Perrier N, Miller M, Freimanis R, Lohman K . DNA-repair genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2003; 12(11 Pt 1):1200-4. View

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

Brewster A, Jorgensen T, Ruczinski I, Huang H, Hoffman S, Thuita L . Polymorphisms of the DNA repair genes XPD (Lys751Gln) and XRCC1 (Arg399Gln and Arg194Trp): relationship to breast cancer risk and familial predisposition to breast cancer. Breast Cancer Res Treat. 2005; 95(1):73-80. DOI: 10.1007/s10549-005-9045-3. View

Smith T, Miller M, Lohman K, Lange E, Case L, Mohrenweiser H . Polymorphisms of XRCC1 and XRCC3 genes and susceptibility to breast cancer. Cancer Lett. 2003; 190(2):183-90. DOI: 10.1016/s0304-3835(02)00595-5. View

Saadat M, Ansari-Lari M . Polymorphism of XRCC1 (at codon 399) and susceptibility to breast cancer, a meta-analysis of the literatures. Breast Cancer Res Treat. 2008; 115(1):137-44. DOI: 10.1007/s10549-008-0051-0. View

10.

Masson M, Niedergang C, Schreiber V, Muller S, de Murcia G . XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol. 1998; 18(6):3563-71. PMC: 108937. DOI: 10.1128/MCB.18.6.3563. View

11.

Hoeijmakers J . Genome maintenance mechanisms for preventing cancer. Nature. 2001; 411(6835):366-74. DOI: 10.1038/35077232. View

12.

Liu L, Yuan P, Wu C, Zhang X, Wang F, Guo H . Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer. 2010; 73(1):110-5. DOI: 10.1016/j.lungcan.2010.11.004. View

13.

Goode E, Ulrich C, Potter J . Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002; 11(12):1513-30. View

14.

Shen M, Jones I, Mohrenweiser H . Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res. 1998; 58(4):604-8. View

15.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

16.

Duell E, Millikan R, Pittman G, Winkel S, Lunn R, Tse C . Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epidemiol Biomarkers Prev. 2001; 10(3):217-22. View

17.

Zhang Y, Newcomb P, Egan K, Titus-Ernstoff L, Chanock S, Welch R . Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2006; 15(2):353-8. DOI: 10.1158/1055-9965.EPI-05-0653. View

18.

Li H, Ha T, Tai B . XRCC1 gene polymorphisms and breast cancer risk in different populations: a meta-analysis. Breast. 2009; 18(3):183-91. DOI: 10.1016/j.breast.2009.03.008. View

19.

Shen J, Gammon M, Terry M, Wang L, Wang Q, Zhang F . Polymorphisms in XRCC1 modify the association between polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, dietary antioxidants, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005; 14(2):336-42. DOI: 10.1158/1055-9965.EPI-04-0414. View

20.

Wood R, Mitchell M, Sgouros J, Lindahl T . Human DNA repair genes. Science. 2001; 291(5507):1284-9. DOI: 10.1126/science.1056154. View